Literature DB >> 20847967

Late outcomes following percutaneous coronary interventions: results from a large, observational registry.

Clare E Appleby1, Karen Mackie, Vladimír Dzavík, Joan Ivanov.   

Abstract

BACKGROUND: Randomized controlled trials report short- and medium- term outcomes following percutaneous coronary intervention (PCI), but their applicability to the general population is not known. Data regarding the long-term clinical outcomes of patients undergoing PCI are lacking.
OBJECTIVE: To determine the long-term outcomes of 'all-comers' undergoing PCI at a large-volume tertiary cardiac referral centre.
METHODS: A total of 12,662 consecutive patients undergoing an index procedure and entered into the University Health Network's (Toronto, Ontario) prospective registry between April 2000 and September 2007 were identified. In-hospital outcomes were assessed. Follow-up data were obtained through linkage to a provincial registry. Kaplan-Meier analysis was performed to calculate unadjusted survival rates, and Cox multiple regression analysis identified independent predictors of late mortality, major adverse cardiac events and all cardiovascular events.
RESULTS: The population included a relatively high-risk patient cohort, with 19% older than 75 years of age, 28% with diabetes, 61% with multivessel disease and 1.3% in cardiogenic shock. Urgent procedures comprised 53% of all cases. The all-cause mortality rate at seven years follow-up was 10.6%. Repeat PCI occurred in 14.2% of patients, and coronary artery bypass grafting in 4.2%. Men showed a significant unadjusted survival advantage compared with women. Procedural characteristics such as incomplete revascularization and residual stenosis, in addition to established risk factors, were predictors of poorer long-term outcomes. Cardiogenic shock was the strongest predictor of late mortality.
CONCLUSION: In the present large registry of 'all-comers' for PCI, longterm major adverse cardiac event rates were low and consistent with outcomes from randomized controlled trials. These data reflect a large cohort in real-world clinical practice, and may help clinicians further characterize and better treat high-risk patients who are undergoing PCI.

Entities:  

Mesh:

Year:  2010        PMID: 20847967      PMCID: PMC2950719          DOI: 10.1016/s0828-282x(10)70411-6

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  27 in total

1.  Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.

Authors:  Gregg W Stone; Cindy L Grines; David A Cox; Eulogio Garcia; James E Tcheng; John J Griffin; Giulio Guagliumi; Thomas Stuckey; Mark Turco; John D Carroll; Barry D Rutherford; Alexandra J Lansky
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

2.  Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention.

Authors:  K M Anderson; R M Califf; G W Stone; F J Neumann; G Montalescot; D P Miller; J J Ferguson; J T Willerson; H F Weisman; E J Topol
Journal:  J Am Coll Cardiol       Date:  2001-06-15       Impact factor: 24.094

3.  Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial.

Authors:  F Kiemeneij; P W Serruys; C Macaya; W Rutsch; G Heyndrickx; P Albertsson; J Fajadet; V Legrand; P Materne; J Belardi; U Sigwart; A Colombo; J J Goy; C M Disco; M A Morel
Journal:  J Am Coll Cardiol       Date:  2001-05       Impact factor: 24.094

4.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.

Authors:  P W Serruys; P de Jaegere; F Kiemeneij; C Macaya; W Rutsch; G Heyndrickx; H Emanuelsson; J Marco; V Legrand; P Materne
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

5.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

6.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

Authors:  D L Fischman; M B Leon; D S Baim; R A Schatz; M P Savage; I Penn; K Detre; L Veltri; D Ricci; M Nobuyoshi
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

7.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-07       Impact factor: 91.245

8.  Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.

Authors:  Issam Moussa; Martin B Leon; Donald S Baim; William W O'Neill; Jeffery J Popma; Maurice Buchbinder; Jay Midwall; Charles A Simonton; Emily Keim; Patrick Wang; Richard E Kuntz; Jeffrey W Moses
Journal:  Circulation       Date:  2004-05-03       Impact factor: 29.690

9.  Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry.

Authors:  Pedro A Lemos; Patrick W Serruys; Ron T van Domburg; Francesco Saia; Chourmouzios A Arampatzis; Angela Hoye; Muzaffer Degertekin; Kengo Tanabe; Joost Daemen; Tommy K K Liu; Eugene McFadden; Georgios Sianos; Sjoerd H Hofma; Pieter C Smits; Willem J van der Giessen; Pim J de Feyter
Journal:  Circulation       Date:  2003-12-22       Impact factor: 29.690

10.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

View more
  4 in total

1.  The 'all comer' Coroflex Please drug-eluting stent registry in Europe and Asia - an overall and transcontinental assessment of the 10-month major adverse cardiac events.

Authors:  Matthias Leschke; Vo Thanh Nhan; Matthias Waliszewski; Vicente Palacios; Iván Horváth; Vladimir A Ivanov; Damras Tresukosol; Panicos Avraamides; André Schneider; Martin Unverdorben
Journal:  Indian Heart J       Date:  2012-08-27

2.  Impact of coexisting multivessel coronary artery disease on short-term outcomes and long-term survival of patients treated with carotid stenting.

Authors:  Josef Veselka; Miloslav Špaček; Martin Horváth; Cyril Štěchovský; Ingrid Homolová; Petra Zimolová; Petr Hájek
Journal:  Arch Med Sci       Date:  2016-07-01       Impact factor: 3.318

Review 3.  Impact of Incomplete Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease: A Systematic Review and Meta-Analysis.

Authors:  Vinayak Nagaraja; Sze-Yuan Ooi; James Nolan; Adrian Large; Mark De Belder; Peter Ludman; Rodrigo Bagur; Nick Curzen; Takashi Matsukage; Fuminobu Yoshimachi; Chun Shing Kwok; Colin Berry; Mamas A Mamas
Journal:  J Am Heart Assoc       Date:  2016-12-16       Impact factor: 5.501

4.  Low major adverse cardiac event rates following bioresorbable vascular scaffold implantation: Impact of implantation technique on treatment outcomes.

Authors:  Anne Venkata Ganeshkumar; Rushikesh Sambhaji Patil; Irfan Khan Hamid
Journal:  Indian Heart J       Date:  2017-06-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.